StreetInsider.com News Articles

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Wed, 20 May 2026 09:00:00 -0400

REDWOOD CITY, Calif., May 20, 2026 (GLOBE NEWSWIRE) -- Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA 2026 at the Hynes Convention Center in Boston. Through presentations and a panel discussion, the Company highlighted how its ECO Synthesis® Manufacturing Platform is advancing the production of siRNA, now enabling stereochemical control while addressing key industry challenges in scalability and sustainability.

At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control of phosphorothioate

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Wed, 20 May 2026 09:00:00 -0400

At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control of phosphorothioate

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Wed, 20 May 2026 09:00:00 -0400

At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control of phosphorothioate

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Wed, 20 May 2026 09:00:00 -0400

At the conference, Codexis presented new data demonstrating, for the first time, full-length siRNA synthesis with precise control of phosphorothioate

Form 10-Q CODEXIS, INC. For: Mar 31

Thu, 07 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260507/26453920.html

Form 10-Q CODEXIS, INC. For: Mar 31

Thu, 07 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260507/26453920.html

Form 8-K CODEXIS, INC. For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453635.html

Form 8-K CODEXIS, INC. For: May 07

Thu, 07 May 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260507/26453635.html

Codexis (CDXS) Tops Q1 EPS by 6c ; Offers Guidance

Thu, 07 May 2026 16:14:17 -0400

Codexis (NASDAQ: CDXS) reported Q1 EPS of ($0.10), $0.06 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.79 million.

GUIDANCE:

Codexis sees FY2026 revenue of $72-76 million, versus the consensus of $74.24 million.

For earnings history and earnings-related data on Codexis (CDXS) click here.

Codexis (CDXS) Tops Q1 EPS by 6c ; Offers Guidance

Thu, 07 May 2026 16:14:17 -0400

Codexis (NASDAQ: CDXS) reported Q1 EPS of ($0.10), $0.06 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $15.2 million versus the consensus estimate of $14.79 million.

GUIDANCE:

Codexis sees FY2026 revenue of $72-76 million, versus the consensus of $74.24 million.

For earnings history and earnings-related data on Codexis (CDXS) click here.

Codexis Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance

Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities

REDWOOD CITY, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the first quarter ended March 31, 2026, and provided a business update.

“Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how

Codexis Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance

Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities

“Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how

Codexis Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance

Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities

“Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how

Codexis Reports First Quarter 2026 Financial Results

Thu, 07 May 2026 16:05:00 -0400

Reports revenue of $15.2 million for the first quarter, company reiterates full-year financial guidance

Three presentations at upcoming TIDES USA annual meeting to feature new data for ECO Synthesis manufacturing platform capabilities

“Next week Codexis will present new data at the TIDES USA annual meeting demonstrating how

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: Opaleye Management Inc.

Tue, 05 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260505/26434485.html

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: Opaleye Management Inc.

Tue, 05 May 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260505/26434485.html

Codexis to share RNA manufacturing advances at TIDES USA

Wed, 29 Apr 2026 09:00:00 -0400

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS) a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, will present new data on ECO Synthesis® Manufacturing Platform and provide an update on regulatory engagement for its enzymatic platform at TIDES USA, held May 11–14 at the Hynes Convention Center in Boston.

As RNAi therapies expand into larger indications, manufacturing scalability, maintaining process control and delivering high-quality product is critical. Codexis will present data demonstrating advances in controlling phosphorothioate stereochemistry, improved ligation efficiency and process performance, alongside the sustainability advantages of

StreetInsider.com News Articles

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA

Form 10-Q CODEXIS, INC. For: Mar 31

Form 10-Q CODEXIS, INC. For: Mar 31

Form 8-K CODEXIS, INC. For: May 07

Form 8-K CODEXIS, INC. For: May 07

Codexis (CDXS) Tops Q1 EPS by 6c ; Offers Guidance

Codexis (CDXS) Tops Q1 EPS by 6c ; Offers Guidance

Codexis Reports First Quarter 2026 Financial Results

Codexis Reports First Quarter 2026 Financial Results

Codexis Reports First Quarter 2026 Financial Results

Codexis Reports First Quarter 2026 Financial Results

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: Opaleye Management Inc.

Form SCHEDULE 13G/A CODEXIS, INC. Filed by: Opaleye Management Inc.

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Codexis to share RNA manufacturing advances at TIDES USA

Form ARS CODEXIS, INC. For: Dec 31